MBX (MBX Biosciences) YoY EBITDA Growth: -31.85% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBX MBX Biosciences Inc MBX
14 GF Score
Price $68.67
! 3 Warning Signs
View Full Analysis

What is MBX Biosciences YoY EBITDA Growth?

MBX Biosciences MBX +2.22% 14 YoY EBITDA Growth is -31.85% as of Jun. 2026. GuruFocus rates MBX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MBX Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -31.85%.

MBX Biosciences's EBITDA per Share for the three months ended in Jun. 2026 was $-0.86.

MBX Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences YoY EBITDA Growth Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -36.80 -478.26 58.04

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.76 76.72 -3.06 26.26 -31.85
MBX
14GF Score
MBX Biosciences Inc MBX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MBX Biosciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-2.679--6.384)/ | -6.384 |
=58.04 %

MBX Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.857--0.65)/ | -0.65 |
=-31.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -31.85% mean?
MBX Biosciences (MBX) has a YoY EBITDA Growth of -31.85% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MBX Biosciences and its competitors.
Is MBX Biosciences' YoY EBITDA Growth too high?
MBX Biosciences' current YoY EBITDA Growth is -31.85%. Overall, MBX Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' YoY EBITDA Growth compare to IRON and CLDX?
MBX Biosciences' YoY EBITDA Growth of -31.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MBX Biosciences and its competitors. MBX Biosciences's current YoY EBITDA Growth is -31.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current YoY EBITDA Growth of -31.85%. The current YoY EBITDA Growth is -31.85%. MBX Biosciences' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For MBX Biosciences (MBX), the current YoY EBITDA Growth is -31.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
14GF Score

Get the complete analysis for MBX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$68.67
Price